Company news
Lakefront Biotherapeutics news in 2026
Lakefront Biotherapeutics's news releases, calls and decks from 2026, newest first.
Lakefront to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
September 8, 2026
Lakefront Biotherapeutics Reports Half-Year 2026 Financial Results and Provides Business Update
August 10, 2026
Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi
July 13, 2026
Acquisition of Own Shares
June 30, 2026
Lakefront Biotherapeutics NV - Acquisition of Own Shares
June 17, 2026
Lakefront Announces Initiation of €50 Million Stock Repurchase Program
June 9, 2026
Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer
June 8, 2026
Lakefront Receives Transparency Notification from Bank of America
May 26, 2026
Galapagos’ Shareholders Adopt All Resolutions Proposed by the Board of Directors at the Annual and Extraordinary Shareholders’ Meetings 2026
April 28, 2026
Galapagos and Gilead Enter into Binding Agreement to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
March 31, 2026
Galapagos Announces Nomination of Gino Santini to its Board of Directors
March 26, 2026
Galapagos Publishes 2025 Annual Report and Announces Annual and Extraordinary Shareholders’ Meetings
March 26, 2026
Galapagos and Gilead in Advanced Discussions to Collaborate on Advancing First in Class T Cell Engager Program for Autoimmune Diseases
March 23, 2026
Galapagos Receives Transparency Notification from Bank of America
March 17, 2026
Galapagos Receives Transparency Notifications from Bank of America
March 10, 2026
Galapagos Creates New Subscription Right Plan
March 6, 2026
Galapagos Appoints Tania Philipp as Chief Human Resources Officer
March 5, 2026
Galapagos Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
February 23, 2026
Galapagos Welcomes Dr. Paulo Fontoura to its Board of Directors
February 19, 2026
Third Arc Bio Announces $52M Series A Extension to Expand Oncology and Immunology & Inflammation Portfolio
February 4, 2026
Galapagos Announces Board Decision to Initiate Wind-Down of Cell Therapy Activities
January 5, 2026